Syncona Share Chat (SYNC)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Syncona	LSE:SYNC	London	Ordinary Share	GG00B8P59C08	ORD NPV

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	271.50p	271.00p	271.50p	-	-	-	0	05:30:11

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Equity Investment Instruments	28.7	5.1	0.8	348.1	1,795.22

Syncona Share Discussion Threads

Showing 18401 to 18423 of 18425 messages

Chat Pages: 737 736 735 734 733 732 731 730 729 728 727 726 Older

Date	Subject	Author	Discuss
10/9/2018 09:40	hxxps://www.morganpryce.co.uk/knowledge-centre/exclusive-news-articles/autolus-has-announced-plans-to-take-up-the-fifth-floor-of-the-mediaworks-buildling/ Autolus rents office space with enough space for around 300 staff. Rent starts in October - they have a lot of clinical trials coming up I guess they're looking to expand.	luxaeterna1	Read Full Thread Reply
08/9/2018 13:06	I hope to be adding on the way up. Has a nice bit of momentum this	volsung	Read Full Thread Reply
08/9/2018 12:17	This is one of those shares that you just lock away and don’t worry about...IMO	ltinvestor	Read Full Thread Reply
08/9/2018 08:27	Very good full-page interview with Martin Murphy, Syncona’s Chief Exec, in today’s Times. Blue Earth, Autolus, and Nighstar mentioned along with an outline of Syncona’s modus operandi.	alan@bj	Read Full Thread Reply
06/9/2018 08:51	I bought Adaptimmune shares yesterday on the basis that if Syncona have invested in the company then they must have something very special...	ltinvestor	Read Full Thread Reply
05/9/2018 19:47	Here we go: PHILADELPHIA and OXFORD, United Kingdom, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”;), New Enterprise Associates 16, L.P., New Enterprise Associates 14, L.P. (“NEA”) and Syncona Portfolio Limited (“Syncona̶1;), to purchase an aggregate of US$100 million of its American Depositary Shares (“ADSs”) in a registered direct offering. The transaction was completed from the company’s shelf registration at a price of $10.00 per ADS. The closing of this offering is expected to take place on or about September 7, 2018, subject to the satisfaction of customary closing conditions. Net proceeds of the offering will be used to advance the company’s wholly owned pipeline of SPEAR T-cell candidates through clinical trials as well as for other general corporate purposes. “This financing strengthens our balance sheet and extends our runway through to late 2020. This gives us strategic flexibility as we enter a potentially transformative period of data from our wholly-owned pipeline,” said James Noble, Adaptimmune’s CEO. “I want to welcome Syncona to our shareholder base as they join NEA and Matrix in this round. We are delighted to receive this support from our key shareholders as we continue building an integrated cell therapy company.”	rambutan2	Read Full Thread Reply
05/9/2018 19:41	And they share these new manufacturing facilities in Stevenage with Autolus: htTps://ct.catapult.org.uk/news-media/manufacturing-news/cell-and-gene-therapy-catapult-opens-manufacturing-centre	rambutan2	Read Full Thread Reply
05/9/2018 19:27	Nasdaq listed in 2015, but a UK based company out of Oxford Uni developed tech. So the Wellcome team will know all about it. httPs://www.adaptimmune.com/	rambutan2	Read Full Thread Reply
05/9/2018 18:59	Syncona have today subscribed for shares in a Nasdaq listed T cell company called Adaptimmune!	ltinvestor	Read Full Thread Reply
05/9/2018 10:17	Frankly it seems that AUTOLUS is onto a winner (IMO). They can demonstrate that it generally works, albeit with significant side-effect hazards, but frankly if you are dying of cancer and this offers an 80-95% chance of total recovery they should have a market for it. I will admit that this is a burgeoning market, with several competitors in the market. In 10 years SYNCONA might be a giant, it has all the right backers.	luxaeterna1	Read Full Thread Reply
29/8/2018 16:39	Blue Earth which is private is now profitable with increasing sales...	ltinvestor	Read Full Thread Reply
29/8/2018 14:04	tx..agreed	douglas fir	Read Full Thread Reply
29/8/2018 13:38	No significance in my view. I invest in private equity type companies such as Melrose and Burford. Syncona is more high risk but has a quality portfolio. If only one, but I expect many more, of its companies is successful the rewards are very high. I also look at the team and financial structure, which in Syncona’s case is unique.	brexitplus	Read Full Thread Reply
29/8/2018 13:29	tx for that B+...do you attach any significance/importance to metrics such as premium/discount,z-score etc to Sync....or are they out of the window as it were?	douglas fir	Read Full Thread Reply
29/8/2018 13:24	Biggest riser in the FTSE250	volsung	Read Full Thread Reply
29/8/2018 12:55	Syncona on the up today. Autolus appears to be up around the $30 mark and Nightstar doing well. I considered buying at 120p when this was BACIT but delayed and only got in at 165p a few months ago. Still good profit not to be sniffed at. There is a very good analysis of Nightstar on www.seekingalpha.com. Apparently there is an important event on 24th September. Also 10th August presentation slides. Conclusions of the article “ Conclusion Nightstar Therapeutics is a promising preclinical biotechnology company focused on gene therapies for the treatment of currently untreatable genetic retinal diseases. Its pipeline so far has shown promising results, with its trial structure providing potential 'downside protection' in case of subpar news for its Phase 3 STAR trial. Additionally, it offers an attractive combination of strong balance sheet (almost entirely cash with no debt), institutional investors with a long-term investment view, and limited cash burn. A potential funding gap that might arise around 2020 should also offer no issue, as the company could either easily return to the capital markets or outlicense the rights to either of its therapies. Most notably, however, is the potential for the stock in September: Not only is it providing investors with data on its second product candidate, but could also deliver a positive surprise with additional data at its R&D Day.“	brexitplus	Read Full Thread Reply
29/8/2018 11:41	Cheers David. Nice to see	volsung	Read Full Thread Reply
29/8/2018 11:40	WTF? Good timing volsung… :-) DL	davidlloyd	Read Full Thread Reply
24/8/2018 11:03	Like the look of SYNC. Bought a small initial stake this morning	volsung	Read Full Thread Reply
23/8/2018 17:59	Bouncing indeed!	audigger	Read Full Thread Reply
23/8/2018 12:21	Naw it's bouncing back up now	luxaeterna1	Read Full Thread Reply
22/8/2018 18:39	It looks like 250 may come tomorrow unless it bounces. I almost sold on the previous high of 282 but didn't and it pulled back sharply only to quickly recover. I wonder if this pattern will repeat itself?	audigger	Read Full Thread Reply
22/8/2018 17:46	I will top up at 250 or there abouts. Would really like to know the identity of the new investment.	brexitplus	Read Full Thread Reply

Chat Pages: 737 736 735 734 733 732 731 730 729 728 727 726 Older

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.